CL2017001188A1 - Métodos y formulaciones para tratar enfermedades vasculares de los ojos. - Google Patents
Métodos y formulaciones para tratar enfermedades vasculares de los ojos.Info
- Publication number
- CL2017001188A1 CL2017001188A1 CL2017001188A CL2017001188A CL2017001188A1 CL 2017001188 A1 CL2017001188 A1 CL 2017001188A1 CL 2017001188 A CL2017001188 A CL 2017001188A CL 2017001188 A CL2017001188 A CL 2017001188A CL 2017001188 A1 CL2017001188 A1 CL 2017001188A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- eyes
- formulations
- vascular diseases
- treat vascular
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 229960002833 aflibercept Drugs 0.000 abstract 1
- 108010081667 aflibercept Proteins 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000005484 gravity Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084003P | 2014-11-25 | 2014-11-25 | |
| US201562147232P | 2015-04-14 | 2015-04-14 | |
| US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001188A1 true CL2017001188A1 (es) | 2017-11-24 |
Family
ID=56009149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001188A CL2017001188A1 (es) | 2014-11-25 | 2017-05-10 | Métodos y formulaciones para tratar enfermedades vasculares de los ojos. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160144025A1 (enExample) |
| EP (1) | EP3224278A4 (enExample) |
| JP (2) | JP2017536414A (enExample) |
| KR (1) | KR20170087950A (enExample) |
| CN (1) | CN107001457A (enExample) |
| AU (1) | AU2015353838A1 (enExample) |
| BR (1) | BR112017009807A2 (enExample) |
| CA (1) | CA2968522A1 (enExample) |
| CL (1) | CL2017001188A1 (enExample) |
| CO (1) | CO2017004715A2 (enExample) |
| EA (1) | EA201791168A1 (enExample) |
| IL (1) | IL252159B (enExample) |
| MA (2) | MA41028A (enExample) |
| MX (1) | MX2017006129A (enExample) |
| PE (1) | PE20170900A1 (enExample) |
| PH (1) | PH12017500834A1 (enExample) |
| SG (1) | SG11201703609UA (enExample) |
| WO (1) | WO2016085750A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2586459T (lt) | 2005-03-25 | 2017-09-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonisto kompozicijos |
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| CN104434770A (zh) | 2006-06-16 | 2015-03-25 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| KR101426125B1 (ko) | 2009-07-06 | 2014-08-06 | 에르피오 세러퓨틱스 인코포레이티드 | 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| JP6437462B2 (ja) | 2013-02-21 | 2018-12-12 | アールエスイーエム・リミテッド・パートナーシップ | 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| EP3273840B1 (en) * | 2015-03-26 | 2024-07-17 | Eyekor, LLC | Image analysis |
| WO2017053566A1 (en) | 2015-09-23 | 2017-03-30 | Aerpio Therapeutics, Inc. | Methods of treating intraocular pressure with activators of tie-2 |
| NZ744185A (en) | 2015-12-30 | 2025-09-26 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| EP3487518A4 (en) | 2016-07-20 | 2020-08-12 | Aerpio Therapeutics LLC | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) |
| US20200056186A1 (en) | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
| US20190300607A1 (en) * | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
| JP7161494B2 (ja) * | 2017-05-06 | 2022-10-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 |
| EP4650360A2 (en) * | 2017-08-18 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Image capillary isoelectric focusing to analyze protein variants in a sample matrix |
| ES2927049T3 (es) * | 2017-11-30 | 2022-11-02 | Regeneron Pharma | Uso de un antagonista del VEGF para tratar trastornos oculares angiogénicos |
| JP7692699B2 (ja) * | 2017-12-22 | 2025-06-16 | サムスン バイオエピス カンパニー リミテッド | Ｖｅｇｆアンタゴニストを含む液体組成物 |
| DK3743091T3 (da) | 2018-01-26 | 2025-01-06 | Univ California | Fremgangsmåder og sammensætninger til behandling af angiogene lidelser under anvendelse af anti-vegf-midler |
| WO2019154776A1 (en) * | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| WO2019173767A1 (en) * | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| PT4364724T (pt) | 2018-05-10 | 2025-12-16 | Regeneron Pharma | Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada |
| EP3836959A4 (en) * | 2018-08-17 | 2022-05-11 | Trican Biotechnology Co., Ltd | ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS |
| WO2020089051A1 (en) | 2018-10-29 | 2020-05-07 | F. Hoffmann-La Roche Ag | Antibody formulation |
| CN109598628B (zh) * | 2018-11-30 | 2022-09-20 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
| MX2021007393A (es) | 2018-12-18 | 2021-09-23 | Novartis Ag | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| CA3138682A1 (en) | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| CN115398559A (zh) * | 2020-04-29 | 2022-11-25 | 诺华股份有限公司 | 用于评估患者眼睛中疾病或病症的活动水平的计算机实施的系统和方法 |
| CA3182893A1 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| US20240239881A1 (en) * | 2020-06-22 | 2024-07-18 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-ang-2 antibody and its usage |
| KR102690020B1 (ko) * | 2020-07-24 | 2024-08-01 | (주)팬젠 | 안과용 액상 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| CN104434770A (zh) | 2006-06-16 | 2015-03-25 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| KR20140014405A (ko) * | 2009-05-28 | 2014-02-06 | 글락소 그룹 리미티드 | 안구 질병을 치료하거나 예방하는데 사용되는 ｔｎｆ-알파 길항제 및 ｖｅｇｆ 길항제의 조합물 |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| JP2014503555A (ja) | 2011-01-13 | 2014-02-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| CN104169299B (zh) * | 2012-01-23 | 2018-06-05 | 瑞泽恩制药公司 | 含抗Ang-2 抗体的稳定化制剂 |
| RS62509B1 (sr) * | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| CN104968678B (zh) * | 2012-12-05 | 2018-12-11 | 诺华股份有限公司 | 靶向epo的抗体的组合物和方法 |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| BR112016000282A2 (pt) * | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
| US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| DE112014005747T5 (de) * | 2013-12-17 | 2016-10-06 | Kymab Limited | Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en not_active Ceased
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko not_active Withdrawn
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017009807A2 (pt) | 2018-02-27 |
| MA40306A1 (fr) | 2019-03-29 |
| US20170080086A1 (en) | 2017-03-23 |
| KR20170087950A (ko) | 2017-07-31 |
| CA2968522A1 (en) | 2016-06-02 |
| US20190117767A1 (en) | 2019-04-25 |
| IL252159A0 (en) | 2017-07-31 |
| JP2021046431A (ja) | 2021-03-25 |
| AU2015353838A1 (en) | 2017-06-08 |
| US11071780B2 (en) | 2021-07-27 |
| EP3224278A1 (en) | 2017-10-04 |
| PH12017500834A1 (en) | 2017-10-30 |
| US20160144025A1 (en) | 2016-05-26 |
| MA41028A (fr) | 2017-10-03 |
| PE20170900A1 (es) | 2017-07-12 |
| JP2017536414A (ja) | 2017-12-07 |
| SG11201703609UA (en) | 2017-06-29 |
| CN107001457A (zh) | 2017-08-01 |
| WO2016085750A1 (en) | 2016-06-02 |
| EP3224278A4 (en) | 2018-07-11 |
| EA201791168A1 (ru) | 2017-09-29 |
| MX2017006129A (es) | 2018-04-10 |
| IL252159B (en) | 2021-03-25 |
| CO2017004715A2 (es) | 2017-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001188A1 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| MX2020001340A (es) | Modelos celulares y terapias para enfermedades oculares. | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| AR103130A1 (es) | Sonda de vitrectomía con un escáner de fibra óptica | |
| PH12016502167A1 (en) | Hdl theraphy markers | |
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| CL2018001258A1 (es) | Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2 | |
| MX2015011131A (es) | Composiciones, formulaciones y metodos para tratar enfermedades oculares. | |
| MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| CL2015002485A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares | |
| MX2017016518A (es) | Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo. | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| PE20151925A1 (es) | Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| ZA202503387B (en) | Semaglutide in medical therapy | |
| GT201700194A (es) | Formulación de combinación de tesofensina y betabloqueante | |
| MX392383B (es) | Metodos para tratar afecciones oculares. | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| MX2016016928A (es) | Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos. | |
| EA201691773A1 (ru) | Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1 | |
| AU2016356504A8 (en) | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |